INTRODUCTION
Hepatocellular carcinoma (HCC) is a high-burden disease that ranks as the fifth most common and the third most lethal tumor worldwide. 1 Its high frequency of recurrence and metastasis, with the 1-year relapse rate of approximately 33% after surgery, leads to a low 5-year survival rate of less than 30%. 2, 3 The lack of basic relevant molecular knowledge and the difficulty in detecting the disease at an early stage results in poor outcomes for such patients. For α-fetoprotein (AFP)-positive HCC patients, AFP is a highly sensitive and specific indicator for post-operative HCC recurrence. 4 However, for patients with normal AFP levels, a universally accepted indicator has not yet been identified. 5, 6 Therefore, the identification of a novel and effective biomarker for HCC, especially for its recurrence and metastasis, can be of significant clinical value.
Ubiquitin C-terminal hydrolase 37 (UCH37), which is a type of deubiquitinating enzyme, is one of the key factors in adjusting the dynamic equilibrium of protein ubiquitin and deubiquitination. [7] [8] [9] In our previous studies, we found a high expression of UCH37 in HCC tissue and that it might be an independent risk factor for disease-free survival (DFS) after surgical resection. Moreover, UCH37 promoted cell migration and invasion in HCC cell lines. 10 Furthermore, we carried out a glutathione S-transferase (GST) pull-down experiment using a purified recombinant GST-UCH37 fusion protein from Huh7 cell total protein. In combination with mass spectrometry and a database search, 63 proteins interacting with UCH37 were ultimately identified. Meanwhile, co-immunoprecipitation with anti-UCH37 antibodies detected interacting proteins from HCC tissue. By combining mass spectrometry and a database search, 27 proteins interacting with UCH37 were identified. 11 A common protein in these two groups is peroxiredoxin 1 (PRDX1).
As a member of the peroxiredoxin family, which belongs to the peroxidase family of antioxidant enzymes, PRDX1 is composed of two conserved cysteines in both the N-terminus and C-terminus that can form disulfide bonds with other molecules. 12 It acts as a molecular chaperone and regulates a variety of biological functions such as cell proliferation, differentiation and apoptosis. 13 PRDX1 plays an important role in several signaling pathways, as exemplified in the AKT, c-Abl, PTEN and p38/MAPK signaling pathways. However, the role of PRDX1 in tumors has not been clearly defined. Opposing opinions have been expressed in previous studies over whether PRDX1 is a tumor promoter or suppressor. Moreover, to our knowledge, no study so far has investigated the association between PRDX1 and UCH37.
In the present study we aimed to assess the value of PRDX1 for predicting HCC recurrence after curative resection and explore the role of PRDX1 in HCC cell migration and invasion in HCC and the adjacent non-tumorous tissues.
MATERIALS AND METHODS

Collection of HCC cases and tissue specimens
Tissues were collected from 48 patients with HCC who had undergone complete resection confirmed by pathological diagnosis at the Liver Cancer Institution of Qidong Hospital (Qidong, Jiangsu Province, China) from February 2002 to August 2006. Table S1 provides a summary of the clinicopathological characteristics of the 48 patients. Tissues from another 12 patients who had undergone complete resection and were pathologically confirmed with HCC at the Liver Cancer Institute, Fudan University (Shanghai, China) from July to August 2014, were also collected. The inclusion criteria were: (i) radical resection for HCC; (ii) no extrahepatic or distant metastasis; (iii) no anti-tumor treatment before the operation, e.g., no interventional therapy, radiochemotherapy or absolute alcohol injection therapy. Normal liver tissue was obtained from one patient with pathologically confirmed liver hemangioma at the Liver Cancer Institute, Fudan University. This study was approved by the Ethics Committees of Zhongshan Hospital of Fudan University and Qidong Hospital of Jiangsu Province. Written informed consent was obtained from the patients.
The 48 patients with HCC had a regular follow-up through outpatient services, telephone, review of medical records and other methods, with complete follow-up data, until October 15, 2009 or cancer recurrence or metastasis, or death. Clinical recurrence and metastasis were determined by ultrasonography (US) or computed tomography (CT), serum AFP level, selective angiography findings or re-resection. Overall survival (OS) was calculated from the resection date to that of death or the end of follow-up. Disease-free survival (DFS) was calculated from the date of resection to the date of the diagnosis of recurrence.
Cell and agents
The Huh7 cell lines were purchased from the Shanghai Institutes for Biological Sciences at the Chinese Academy of Sciences (Shanghai, China). UCH37-L02, as established in our previous study, 10 is a UCH37-overexpressing monoclonal cell line. The primary antibodies used in this study were purchased from Abcam Biotechnology (Eugene, OR, USA 0 -GCTCTGTGGAT-GAGACTTTGA-3 0 ; LV5NC-Huh7 and LV3NC-Huh7, Huh7 cells carrying an empty vector, were used as control cells for PRDX1-Huh7 and shPRDX1-Huh7, respectively. LV5NC-UCH37-L02 and LV3NC-UCH37-L02, UCH37-L02 cells carrying an empty vector were used as control cells for PRDX1-UCH37-L02 and shPRDX1-UCH37-L02, respectively.
Real-time polymerase chain reaction (PCR)
Cells were collected and the total RNA was extracted and reversely transcribed into cDNA according to the manufacturer's instructions of the SYBR reagent 
Western blot
Appropriate protein lysis buffer was added to the collected cells and then repeatedly pipetted to collect cellular total protein after centrifugation, followed by the determination of the protein concentration. Loading buffer was added to the protein samples and they were then heated in 100 C boiling water for 8 min for Western blot preparation. Protein samples were electrophoresed on 12% sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) gels and transferred to nitrocellulose membranes (Amersham Biosciences, Piscataway, NJ, USA). The membranes were blocked in blocking solution [50 mmol/L Tri-HCl, 150 mmol/L NaCl, 5% (w/v) defat dry milk and 0.1% Tween-20] at room temperature for 1 h, followed by incubation with appropriate primary antibodies at 4 C overnight. The membranes were then incubated with appropriate secondary antibodies at room temperature for 1 h. Finally, we added drops of enzyme-linked chemiluminescence reagent (Pierce) and the samples were placed into a LAS3000 imaging system (Fuji, Tokyo, Japan) for exposure and image recording.
Co-immunoprecipitation (Co-IP)
We collected cellular total proteins and added 2 μg of the appropriate antibody, then rotated them at 4 C for 10 h. The relevant protein A-agarose (Roche, Basel, Switzerland) was then added before rotating overnight at 4 C. Precipitates were collected through centrifugation at 6000 ×g, and the protein A-agarose was washed by lysis buffer, retrieving the precipitates for Western blot analysis.
Immunohistochemical (IHC) stain
After deparaffinization and hydration, paraffin sections were added to a 95-100 C preheated citrate solution (pH 6.0) and were heated by low-energy microwave for 15 min for antigen retrieval. After being washed with phosphate-buffered saline (PBS), the samples were incubated with 10% goat serum at 25 C for 30 min. Anti-PRDX1 monoclonal antibody was then added by drops and the sections were incubated overnight at 4 C. After having been washed with PBS and drops of biotinylated secondary antibody having been added, the sections were blocked at 25 C for 30 min before immunostaining with a 3,3'-diaminobenzidine (DAB) hydrochloric acid kit (Boster, Pleasanton, CA, USA). They were then restained with hematoxylin and eosin (HE). Finally, samples were dehydrated, dried and mounted.
We evaluated the results of immunohistochemistry using Friedrich's criteria: 0, non-staining; 1, light yellow; 2, pale brown; and 3, dark brown. Interpretation scores of the extent of staining positivity of cells were as follows: zero point was scored if the ratio of DAB hydrochloric acid-stained cells over counted cells was ≤5%, one point for a ratio of 6-20%, two points for a ratio of 21-50% and three points for a ratio ≥51%. The final score was the product of the intensity of staining and the stained cell ratio. A score greater than two was considered positive, while that equivalent to or smaller than two was considered negative. Two pathologists evaluated the degree and extent of the dyeing independently, and a consensus review was held for any discrepancy.
Confocal laser imaging
The cells were inoculated in culture plates with clean sterile coverslips and incubated in a 37 C incubator for 24 h. They were then fixed by acetone-formaldehyde and 5% FBS was added before incubation in a 37 C incubator for 1 h. The cells were washed in phosphatebuffered saline plus 0.2% Triton X-100 (PBS-T) and the appropriate primary antibody was added, it was then incubated overnight at 4 C. After being washed in PBS-T and the appropriate fluorescence secondary antibody was added, the cells were incubated at room temperature in dark for 1 h. Then we stained the nucleus with 4',6-diamidino-2-phenylindole (DAPI). After the cells were washed in PBS-T, the coverslip was removed and mounted with fluorescence quencher for observation and imaging via a confocal laser scanning microscope (TCS SP5; Leica, Mannheim, Germany).
Cell scratch assay
The cells (1 × 10 5 ) were seeded in a 6-well culture dish. When the cells covered 95% of the dish surface, we scratched the center of the culture dish with a blue sterilized micropipette tip. The width of the scratch was the same in both the control cells and the PRDX1-Huh7 and shPRDX1-Huh7 cells. After washing out the cellular debris with PBS, the cells were cultured for another 48 h after the scratch. Cell migration (change in scratch width) was then observed under an optical microscope (Olympus, Tokyo, Japan) and the images were recorded.
Cell proliferation and cell colony formation assay
For the cell proliferation assay, 1 × 10 3 cells were grown in 96-well plates and cultivated for 24 h. Cell proliferation activity was then measured using a CCK-8 kit (MedChemExpress, Monmouth Junction, NJ, USA) at different time points according to the manufacturer's instructions. For the cell colony formation assay, cells (at 100 cells/well) were seeded into 6-well plates and cultured for 2 weeks. The cells were then fixed with 4% paraformaldehyde and stained with Giemsa to visualize colonies for counting. The number of clones formed = (number of clones/number of inoculated cells) × 100.
Cell transwell migration and invasion tests
In the cell transwell migration test, 100 μL (approximately 10 4 ) of cells were grown in a transwell chamber (8 μm, 24-well cell culture plate). The upper culture solution was 1% bovine serum albumin (BSA) while the lower culture solution was a culture medium containing 15% FBS. The cells were placed in a 5% carbon dioxide incubator at 37 C for 48 h. After carefully wiping off the cells from the upper chamber with a cotton swab, the samples were fixed and stained in accordance with the standard method. We counted the number of cells in four independent fields under an optical microscope (Olympus).
In the cell transwell invasion test, Matrigel membrane matrix was diluted to nine parts of serum-free medium. Then, 100 μL of the liquid membrane was evenly spread in the transwell chamber and placed in a 37 C incubator chamber for 8-10 h, allowing the membrane to solidify naturally. After that, 100 μL (approximately 10 4 ) of cells were grown in the transwell chamber (8 μm, 24-well cell culture plate) covered with Matrigel membrane. The remaining procedures were similar to the cell transwell migration test.
Statistical analysis
Statistical analyses were performed using SPSS 21.0 (IBM, Armonk, NY, USA). Variables for transwell tests were expressed as mean AE standard deviation. Data were analyzed using the t-test or χ 2 test or Fisher's exact probability test. A Cox proportional hazards regression model, Kaplan-Meier survival estimate and log-rank test were used to assess the relationship between PRDX1 expression and prognostic significance. P < 0.05 was considered as statistically significant.
RESULTS
Relationship between PRDX1 expression and the clinicopathological characteristics of HCC and its influence on HCC recurrence and prognosis analysis. HCC tissues showed a lower PRDX1 expression compared with that in the adjacent noncancerous tissues in most cases (Fig. 1) . We then conducted IHC detection of PRDX1 in the 48 pairs of HCC tissues and corresponding adjacent noncancerous tissues (Fig. 2) , which showed a 77.1% (37/48) positive result (a score greater than two using Friedrich's criteria) for PRDX1 in HCC tissue, which was remarkably lower than that of the adjacent tissues (91.7%, 44/48) using χ 2 test, with statistical significance (P = 0.004).
The score of adjacent non-cancerous tissue was mostly higher than that of the tumor tissue in these positive cases. Hence, we further investigated whether the difference in score between adjacent non-cancerous tissue and HCC tissue was associated with patient prognosis. Univariate analysis indicated that positive HBsAg, elevated serum γ-glutamyl transpeptidase (GGT; >54 U/L), large tumor size (>5 cm), multiple tumors, a higher TNM stage (II-III), the absence of tumor encapsulation and the presence of vascular invasion were parameters for a poor OS and DFS (Table 1) . Meanwhile, compared with adjacent non-cancerous tissue, lower PRDX1 in HCC tissues was also found to be an unfavorable predictor of poor OS and DFS. Patients with adjacent non-cancerous tissue scored by higher than two HCC; adjacent non-tumorous tissues. *P < 0.05; **P < 0.01. points or more than tumor tissue had shorter OS (25 months vs 44 months, P = 0.002; Table 1 , Fig. 3a ) and lower DFS (24 months vs 44 months, P = 0.001; Table 1 , Fig. 3b ) after surgery. On multivariate analysis, the results showed that positive HBsAg and lower PRDX1 expression in the tumor tissue were independent risk factors for post-resection OS and DFS (Table 2) .
Moreover, we performed a correlation analysis between PRDX1 expression with other clinicopathological characteristics, and the results showed a The overall survival and (b) disease-free survival of ( ) patients whose score of PRDX1 for adjacent non-cancerous tissue was higher than that of the HCC tissue by two points or more (Group 1) were obviously shorter compared with ( ) those whose score difference was less than two (Group 2). The comparison was performed using log-rank method.
Group 1 censored; Group 2 censored.
correlation between lower PRDX1 expression and high serum GGT level (Table 3 ).
PRDX1 expression in HCC cell lines and the establishment of stable PRDX1-overexpressing and silencing monoclonal cell lines
Western blot and real-time PCR analyses showed a decline in PRDX1 expression in several different human HCC cell lines (MHCC-97L, HccL-M3, Hep3b, Huh7, MHCC-97H, SMMC-7721) compared with the normal human liver cell line L02 (Fig. 4) . We selected the Huh7 cell line to establish PRDX1-overexpressing cells (PRDX1-Huh7) and silenced monoclonal cell lines (shPRDX1-Huh7). Western blot and real-time PCR results indicated this establishment succeeded (Fig. 5 ).
PRDX1 inhibited cell proliferation
To evaluate the role of PRDX1 in HCC cell proliferation, a CCK-8 assay was carried out. The proliferation of HCC exhibited an obviously decreased rate in PRDX1-Huh7 cells compared with the control cells (LV5NC-Huh7; cells with an empty vector). The inhibition of PRDX1 expression significantly promoted cell proliferation (Fig. 6a ). In the cell colony formation assay, PRDX1-Huh7 cells formed fewer colonies than LV5NC-Huh7 cells (P = 0.0012; Fig. 6b ), while the clonogenicity of Huh7 cells was increased after PRDX1 expression was suppressed (P = 0.0003; Fig. 6c ).
PRDX1 restrained cell migration and invasion
We decided to explore the relationship between PRDX1 and cell migratory and invasive abilities because intrahepatic recurrence and distal metastasis are associated with a poor prognosis for HCC. The cell scratch tests showed that PRDX1-silenced cells migrated into the wound area more aggressively than cells carrying an empty vector (LV3NC-Huh7 cells) (Fig. 7a,b) . Fig. 7f,g ). These data suggested that the migration and invasive capabilities of PRDX1-overexpressing cells was weakened significantly.
An interaction existed between PRDX1 and UCH37
In our preliminary study we found that PRDX1 was one of the proteins in the UCH37 precipitate. 11 The co-IP results showed that UCH37 was detected in the co-precipitation based on the anti-PRDX1 antibody in the Huh7 cells (Fig. 8a) and PRDX1 was also easily detected in the anti-UCH37 antibody-based coprecipitation (Fig. 8b) . This indicated that PRDX1 and UCH37 existed in the same complex, implying that there was an interaction between PRDX1 and UCH37.
Through confocal laser scanning we found that PRDX1 was distributed mainly in the cytoplasm, while UCH37 was distributed in both the nucleus and cytoplasm. The distribution of these two proteins in the cytoplasm overlapped (Fig. 8c) . Meanwhile, confocal laser scanning showed that the distributions of PRDX1 and UCH37 in HCC tissues, adjacent noncancerous tissue and normal liver tissue overlapped (Fig. 8d) . These data suggested that PRDX1 and UCH37 were co-localized both in cells and tissues. 
PRDX1 inhibited the migration and invasion of UCH37-overexpressing cells
In our previous studies we found that in HCC tissue, higher UCH37 expression was an independent risk factor for HCC recurrence after radical resection. Moreover, we found that UCH37 promoted cell invasion and migration in HCC cell lines. 10 In the current study PRDX1 was sustainably overexpressed or silenced in UCH37-L02 cells, namely, PRDX1-UCH37-L02 and shPRDX1-UCH37-L02, respectively. Western blot and real-time PCR results indicated the establishment of the cells was successful (Fig. 9) .
Cell scratch assays and transwell migration assays showed that compared with cells with empty vector, PRDX1 overexpression in UCH37-L02 cell lines weakened their ability for cell migration remarkably, while PRDX1 silencing significantly enhanced cell migration. Transwell invasion assays produced similar results that the invasive capability of UCH37-L02 cells with PRDX1 overexpression was remarkably weakened compared with cells with empty vector, while PRDX1 silencing strengthened UCH37-L02 cell invasion capability (Fig. 10) .
Compared with the corresponding control (cells with empty vector), UCH37 overexpression did not influence the expression of PRDX1. Similarly, PRDX1 overexpression or silencing did not influence the expression of UCH37 (Fig. S1) .
DISCUSSION
HCC is a tumor with a poor clinical prognosis. 14 Existing research has shown that PRDX1 is associated with tumors. Some studies have reported the upregulation of PRDX1 in some types of cancers, e.g., thyroid, 15 breast, 16, 17 lung, 18 bladder, 19 prostate cancers, 20, 21 esophageal squamous cell carcinoma 22 and pancreatic cancer 23, 24 . The overexpression of PRDX1 in such cancers is related to carcinogenesis, cancer development, recurrence and poor prognosis of the patients. PRDX1 expression is also elevated in patients with breast cancer who had a poor response to docetaxel. 25 Other studies have shown that PRDX1 is involved in tumor suppression. Neumann et al. established that Prdx1-knockout mice had a short lifespan due to the development of severe hemolytic anemia and several malignant cancers starting at 9 months of age. 26 Chen et al. showed that lower PRDX1 activity increased radiotherapy sensitivity in both A549 and H1299 lung cancer cell lines. 27 In our study, PRDX1 was found to be expressed at a lower level in HCC tissue than in the adjacent noncancerous tissue. Univariate and multivariate analyses showed that positive HBsAg, which had been well recognized in previous studies, and a difference greater than or equivalent to two between PRDX1 IHC scores in adjacent non-cancerous tissue and HCC tissue were independent risk factors for post-HCC resection OS and DFS. We found in the current study that PRDX1 might be a novel HCC prognostic marker for clinical application and indicated that PRDX1 played an important role in the development of HCC. In addition, lower PRDX1 expression was related to higher serum GGT level, suggesting that high serum GGT may have a clinical value for HCC.
This study was a retrospective cohort study with a limited sample size. AFP is a well-known valuable diagnostic marker. However, no prognostic value of AFP was found in this study. Then we checked the original data and found that higher AFP was more likely to be found in patients with recurrence than in those without (74.1% vs 61.9%). Therefore, we thought that the lack of a meaningful value for AFP in our analysis was possibly due to the limited sample size. Similarly, there was a meaningful value in some other well recognized independent risk factors for HCC, such as TNM stage, vascular invasion and tumor encapsulation, in univariate analysis but not in the multivariate analysis. Large-sample-sized well-designed randomized controlled clinical trials are needed to validate our results. It is well-known that reactive oxygen species (ROS) play crucial roles in oxidative stress, 28, 29 and PRDX1 can efficiently eliminate ROS. The relationship between PRDX1 and tumors has attracted attention in recent years. A review of the literature has suggested that PRDX1 is involved in several cell signaling pathways. Overexpression of PRDX1 suppresses tumor necrosis factor (TNF)-α-induced nuclear factor (NF)-κB transcriptional activity. 30 Kim et al. 31 reported that PRDX1, together with GSTpi, binded to JNK, leading to the repression of radiation-induced JNK signaling and was directly associated with the c-AbI SH-3 domain. Moreover, the highly conserved 15-20 amino acid region of C-Myc, known as Myc-Box II, which is critically important for transformation and transcriptional activity, has also been found to be bound by PRDX1. 32 Leslie et al. 33 showed that phosphatase and tension homolog (PTEN) oxidation in stimulated macrophages led to not only the temporary suppression of its phosphatase behavior but also Akt downstream activation via its phosphorylation at serine 473. It has been proposed that PTEN lipid phosphatase behavior is protected by PRDX1 against oxidation-induced inactivation, through which Aktdriven tumorigenesis is prevented. 34 Rawat et al. found that PRDX1 correlated with MST1, a tumor suppressor, and resulted in the further activation of Mst1 by a feedback loop. 35 Several studies have demonstrated the ability of PRDX1 to act as a signal peroxidase in transmitting peroxide signals to the ASK1/p38/MAPK pathway. 36 However, Ha et al. 37 have shown that the overexpression of PRDX1 can enhance transforming growth factor β1-induced epithelial-mesenchymal transition and promote cell migration in cancer cells. Recently, studies have suggested that PRDX1 acts as an endogenous danger signal by binding to toll-like receptor 4 (TLR4), causing increases in vascular endothelial growth factor (VEGF) expression and the chronic activation of tumor angiogenesis. 21, 38 All the available evidence suggests that PRDX1 plays dual roles in tumorigenesis, tumor progression and prognosis.
Our study showed that PRDX1 silencing could promote HCC cell proliferation, migration and invasion in vitro remarkably, which is consistent with the results of our previous clinical research. Since cell migration and invasive capabilities are associated with tumor recurrence, we propose that PRDX1 may be a novel marker for predicting HCC recurrence. In our previous studies we have verified that UCH37 is related to HCC recurrence and that it promotes HCC cell migration and invasion. At the same time, PRDX1 was picked up in a screen via proteomics techniques Figure 9 . Stable peroxiredoxin 1 (PRDX1)-overexpressing and -silenced monoclonal cell lines in ubiquitin C-terminal hydrolase 37 (UCH37)-L02 were established and verified by (a,b) real-time polymerase chain reaction analysis (PCR) and (c,d) Western blot. β-actin and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) were used as controls, respectively, for real-time PCR and Western blot. ***P < 0.001. UCH37-L02, UCH37 sustainably overexpressed in L02 cells; LV5NC-UCH37-L02 and LV3NC-UCH37-L02, UCH37-L02 cells with empty vectors; PRDX1-UCH37-L02 or shPRDX1-UCH37-L02, PRDX1 sustainably overexpressed or silenced in UCH37-L02 cells.
as a protein that interacts with UCH37. In this study, we further verified the interaction between PRDX1 and UCH37 via co-IP and confocal laser microscopy. Furthermore, we constructed PRDX1 overexpressing and silencing in UCH37-overexpressing monoclonal cell lines and further investigated the interaction between PRDX1 and UCH37. The results showed that PRDX1 weakened the capability of UCH37 to promote cell migration and invasion, presumably due to their interaction. This implies that PRDX1 can inhibit HCC cell migration and invasion, partly through a UCH37-relevant pathway. However, the expression of PRDX1 or UCH37 did not result in any significant changes in their respective expressions. Therefore, we deduce that UCH37 may play a role in tumor processes by forming a complex with PRDX1 instead of regulating PRDX1 via deubiquitination followed by degradation.
In conclusion, this study is, to our knowledge, the first to demonstrate that PRDX1 restrains cell migration and invasion in HCC cell lines and that PRDX1 is an independent risk factor for post-HCC resection OS and DFS. Moreover, we explored whether PRDX1 has the capacity to weaken the promotive effect of UCH37 for cell migration and invasion via their interaction, indicating that PRDX1 involvement in HCC cell migration and invasion was mediated in part by a UCH37-relevant pathway. Hence, we believe that PRDX1 could be a novel effective biomarker for predicting HCC recurrence. More in-depth studies are needed to clarify the mechanism by which PRDX1 interacts with UCH37 in HCC. 
